Design expert software assisted development and evaluation of empagliflozin and sitagliptin combination tablet with improved in-vivo anti-diabetic activities

BACKGROUND: The combination of empagliflozin and sitagliptin to treat type-2 diabetes might be more economical and patient compliance with an additive improvement in glycemic control due to complementary modes of action. AIM OF THE STUDY: To design, formulate and optimize an immediate tablet dosage...

Descripción completa

Detalles Bibliográficos
Autores principales: Hossain, Md Saddam, Jahan, Sadia, Al Rezwan Rahman, Sad, Rahman, Mashiur, Kumar, Diponkor, Paul, Susmita, Chandra Rajbangshi, Joy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10015239/
https://www.ncbi.nlm.nih.gov/pubmed/36938401
http://dx.doi.org/10.1016/j.heliyon.2023.e14259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10015239/
https://www.ncbi.nlm.nih.gov/pubmed/36938401
http://dx.doi.org/10.1016/j.heliyon.2023.e14259

Ejemplares similares